Showing 3691-3700 of 8864 results for "".
- Study: Questionable Efficacy for Complementary and Alternative Skin Care Therapieshttps://practicaldermatology.com/news/study-evaluates-efficacy-of-alternative-therapies-in-skin-care/2475123/Complementary and alternative medicines (CAMs) commonly used in dermatology lack high-quality evidence needed to support their efficacy, according to a comprehensive literature review from researchers at Baylor College of Medicine.
- New IL-13/IL-31R Bispecific Antibody Data Presented at EAACIhttps://practicaldermatology.com/news/New-IL-13-IL-31R-Bispecific-Antibody-Data-Presented-EAACI/2475170/A new IL-13/IL-31R bispecific antibody demonstrated ability to simultaneously suppress the inflammatory and pruritogenic pathways in atopic dermatitis (AD), according to preclinical study data presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, S
- NEMLUVIO Demonstrates Durable Efficacy and Safety in Atopic Dermatitishttps://practicaldermatology.com/news/nemluvio-demonstrates-durable-efficacy-and-safety-in-atopic-dermatitis/2475110/New two-year interim data from the ARCADIA long-term extension study of NEMLUVIO (nemolizumab) showed sustained improvements in skin and itch outcomes. The therapy was approved by the FDA in December 2024 for the treatment of
- Bimekizumab 3-Year Data Shows Lasting Efficacy, Control of Inflammation for PsA, axSpAhttps://practicaldermatology.com/news/Bimekizumab-3-Year-Data-Shows-Lasting-Efficacy-Control-Inflammation-PsA-axSpA/2475126/Bimekizumab (BIMZELX®) demonstrated sustained control of inflammation and deep efficacy in patients living with psoriatic arthritis (PsA) and active axial spondyloarthritis (axSpA), according to new 3-year data from phase 3 trials and open-label extensions in adults with active PsA and active axS
- AB Chopra Epigenetics Launches With Plan to Revolutionize Longevityhttps://practicaldermatology.com/news/AB-Chopra-Epigenetics-Launches-With-Plan-Revolutionize-Longevity/2475124/Charles Rosier, co-founder of the Augustinus Bader skincare and biotech company, and Deepak Chopra, MD, announced the launch of AB Chopra Epigenetics, a revolutionary longevity platform that merges advanced artificial intelligence, epigenetic science, and consciousness-based healing to redefine t
- Analysis: Methotrexate Does Not Enhance Adalimumab Outcomes in Psoriasishttps://practicaldermatology.com/news/methotrexate-does-not-enhance-adalimumab-outcomes-in-psoriasis/2475072/Concomitant methotrexate does not improve the effectiveness or persistence of adalimumab in plaque psoriasis, according to findings from a new study. Researchers investigating whether methotrexate enhances adalimumab’s durab
- Researcher Elaborates on Vitamin D Pretreatment to Enhance PDT for AKhttps://practicaldermatology.com/news/Researcher-Elaborates-Vitamin-D-Pretreatment-Enhance-PDT-AK/2475053/Vitamin D pretreatment can enhance photodynamic therapy (PDT) treatment of actinic keratoses (AK), and vitamin D receptor alleles correlate with serum vitamin D levels and squamous neoplasia, dermatology resident Taylor Bullock, MD, showed in a presentation at the Noah Worcester Dermatological So
- The Future of Psoriasis: Improving Efficacy, Access, and Morehttps://practicaldermatology.com/news/Future-Psoriasis-Improving-Efficacy-Access-More/2475040/The biologic revolution in psoriasis may only be getting started. In a presentation at the Noah Worcester Dermatological Society meeting in Quebec City, Quebec, Ronald Vender, MD, made eight predictions for the future of psoriasis treatments, with impacts ranging from efficacy to affordabi
- Study: Lifileucel Shows Sustained Benefit in Advanced Melanoma Over 5 Yearshttps://practicaldermatology.com/news/lifileucel-shows-sustained-benefit-in-advanced-melanoma-over-5-years/2475031/Lifileucel showed sustained benefit and safety in a 5-year follow-up analysis of the phase II C-144-01 study in patients with advanced melanoma, according to a new study in the Journal of Clinical Oncology. Patien
- Huma Announces AI Tool to Automate Clinical Notes and Billinghttps://practicaldermatology.com/news/huma-announces-ai-tool-to-automate-clinical-notes-and-billing/2475018/Huma Therapeutics announced the launch Hi Scribe, a generative AI tool for automating clinical documentation and billing, according to a press release from the manufacturer. Huma Therapeutics, a UK- and US-based digital healt